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Colorectal cancer (CRC) screening reduces CRC incidence and mortality. Risk models based 
on phenotypic variables have relatively good discrimination in external validation and may 
improve efficiency of screening. Models incorporating genetic variables may perform better. 
In this review we updated our previous review by searching Medline and EMBASE from the 
end date of that review (January 2014) to February 2019 to identify models incorporating at 
least one single nucleotide polymorphism (SNP) and applicable to asymptomatic individuals 
in the general population. We identified 23 new models, giving a total of 29. Of those in 
which the SNP selection was based on published GWASs, in external or split-sample 
validation the AUROC was 0.56-0.57 for models including SNPs alone, 0.61-0.63 for SNPs 
in combination with other risk factors and 0.56 to 0.70 when age was included. Calibration 
was only reported for four. The addition of SNPs to other risk factors increases 
discrimination by 0.01-0.05. Public health modelling studies suggest that, if determined by 
risk models, the range of starting ages for screening would be several years greater than using 
family history alone. Further validation and calibration studies are needed alongside 







Colorectal cancer (CRC) is the second leading cause of cancer-related death in Europe and 
the United States (1). There is good evidence that screening adults in the general population 
who are at average risk with faecal occult blood testing, flexible sigmoidoscopy or 
colonoscopy reduces CRC incidence and mortality (2–7).  However, as with all screening 
programmes, CRC screening has the potential to cause harm, both directly to those screened 
and indirectly through diversion of resources away from other services. Targeted or stratified 
screening could potentially provide a way of reducing complication rates and demand on 
services while still ensuring those at greatest risk are effectively screened. For example, the 
U.S. Multi-Society Task Force on Colorectal Cancer endorse a risk-stratified approach with 
faecal immunochemical testing (FIT) screening in populations with an estimated low 
prevalence of advanced neoplasia and colonoscopy screening in high prevalence 
populations(8). 
 
We have previously published a systematic review of risk prediction models for CRC and 
identified 40 models that have been developed and could potentially be used for risk 
stratification(9). These range from models including only data routinely available from 
electronic health records, such as age, sex and body mass index, to more complex models 
containing detailed information about lifestyle factors and genetic information. Using the UK 
Biobank cohort for external validation we have shown that several of those including only 
phenotypic risk factors and/or family history exhibit reasonable discrimination in a UK 
population (10). At the time of the literature search for that review (January 2014) only six 
risk models incorporating genetic risk factors and predicting future risk of developing CRC 
had been published, and their performance was similar to models including only phenotypic 
information. Since then, findings from genome-wide association studies have resulted in a 
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rapid rise in the number of published risk models incorporating genetic information. 
Simulation studies have also shown that using genetic information to stratify screening has 
the potential to improve efficiency (11) by reducing the number of individuals screened while 
still detecting as many cases (12). It is not clear, however, which genetic risk models perform 
best, how much combining common genetic variants with phenotypic risk factors improves 
model performance, or the potential public health impact of incorporating these models into 
screening programmes. 
 
In order to inform future stratification of CRC screening using genetic data, we have updated 
our previous systematic review to identify and synthesize the performance of all published 
CRC prediction risk models that include common genetic variants and estimates of the 
potential public health impact of stratifying populations for screening based on genetic risk. 
 
MATERIALS AND METHODS 
We updated a previous systematic review following a published study protocol (PROSPERO 




We searched Medline, EMBASE and the Cochrane Library from January 2014 (the end date 
of the search in our previous review) to February 2019 applying the same search strategy 
used in our previous review, with no language limits (see Supplementary Materials and 
Methods S1, for complete search strategy for Medline and EMBASE). We subsequently 





We included studies if they met all of the following criteria: (i) were published as a primary 
research paper in a peer-reviewed journal;  (ii) provided a measure of relative or absolute risk 
using a combination of two or more risk factors, including at least one single-nucleotide 
polymorphism (SNP), that allows identification of individuals at higher risk of colon, rectal 
or colorectal cancer, or advanced colorectal neoplasia; (iii) reported a measure of 
discrimination (e.g. C-statistic, area under the receiver operating characteristic curve 
(AUROC)), or calibration (e.g. Hosmer-Lemeshow statistic, Observed/Expected ratio) , or a 
quantitative estimate of the implications of using the risk model for stratified screening; and 
(iv) included data applicable to the general population (i.e. the risk model was not specifically 
designed for individuals known to carry specific high-risk mutations or from families with a 
known cancer syndrome, such as familial adenomatous polyposis or hereditary nonpolyposis 
colorectal cancer). As in our previous review, studies including only highly selected groups, 
for example immunosuppressed patients, organ transplant recipients, or those with a previous 
history of colon and/or rectal cancer were excluded. We also included studies published prior 
to January 2014 that had been identified in our previous review if they met the above criteria. 
 
One reviewer (LM) performed the search and screened 67% of the titles and abstracts to 
exclude papers that were clearly not relevant. The remaining 33% of titles and abstracts were 
divided between four reviewers (JUS, SG, JE, FW) for screening. The four reviewers also 
each independently assessed a random selection of 3% of the papers screened by LM. The 
full-text of all papers for which a definite decision to reject could not be made from the title 
and abstract alone were independently assessed by two reviewers (LM and JUS/SG/JE/FW). 
Those assessed as not meeting the inclusion criteria by both researchers were excluded. 
Those for which it was not clear were discussed with the wider research team. One paper was 




Data extraction and synthesis 
Data were extracted independently by two researchers (LM and JUS/SG/JE) directly into data 
tables to minimize bias. These tables included details on: (i) the development of the model, 
including potential sources of bias such as the selection processes for participants and SNPs; 
(ii) the risk model itself, including the variables included; (iii) the methods of model 
development (genetic and phenotypic components); (iv) the performance measures 
(discrimination (e.g. C-statistic, AUROC), or calibration (e.g. Hosmer-Lemeshow statistic, 
Observed/Expected ratio) of the risk model in the development population; (v) any external 
validation studies of the risk model, including the study design and performance of the risk 
model; and (vi) any public health modelling of the potential impact of using the risk models 
in practice. In papers that reported performance data for multiple step-wise models developed 
in the same population we included only the best performing model in our main analysis. If 
performance data were presented separately for a model including only SNPs and a model 
including both SNPs and phenotypic variables in the same paper, these were considered as 
two models. If performance data were presented separately for models that incorporated the 
same SNPs but were developed using unweighted allele counting or with allele weights 
derived either from the literature or the study population, we extracted both sets of data. To 
assess the incremental effect on performance of incorporating SNPs into the risk models, we 
additionally extracted data on the performance of the models including only phenotypic risk 
factors and/or family history, where they were reported.  
 
At the same time as data extraction, an overall assessment of risk of bias was performed 
using four domains from the CHARMS checklist (study population, predictors, outcome and 
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sample size and missing data)(13). We also classified studies into the following groups 
according to the TRIPOD guidelines(14):  
 development only (1a);  
 development and validation using resampling (1b);  
 random (2a) or non-random (2b) split-sample development and validation; 
 development and validation using separate data (3); or  
 validation only (4).  
 
For the models including only SNPs, a model developed using SNPs selected from the 
literature, either with unweighted allele counting, or with allele weights derived from the 
literature, was considered as group 3 (development and validation using separate data). 
However, if the model used weights derived from the study population, or if the model 
included only the SNPs found to be significantly associated with CRC in the study 
population, we assigned it to either group 1b, 2a, 2b or 3, depending on the relationship 
between the study population and the testing population. Simulated populations were 
considered external populations. 
 
RESULTS 
From 12,394 papers we excluded 12,277 at title and abstract level and a further 103 after full-
text assessment. After title and abstract screening by the first reviewer, no additional papers 
met the inclusion criteria in the random 12% screened by a second reviewer. There was also 
complete agreement amongst researchers at the full-text level with the most common reasons 
for exclusion being that the papers did not include a risk score (n=43), were conference 
abstracts (n=19) or did not include any performance measures (n=23) (Supplementary Figure 
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S1). Four were also excluded as they described models that were developed to detect 
prevalent undiagnosed disease rather than estimate future incident disease risk. 
 
A further four papers were identified through citation searching. The addition of four papers 
(six risk models) which had been included in our previous systematic review gave a total of 
22 papers describing 29 risk models for inclusion in the analysis. Table 1 summarizes these 
29 risk models. Except for the model by Weigl et al., (15) that included CRC or advanced 
adenoma as the outcome, all had CRC as the outcome. The paper by Jung et al., (16) 
developed separate models for colorectal, colon and rectal cancer. As these were the only 
models for colon and rectal cancer, we included only the model for colorectal cancer in the 
analysis. Nine models included only SNPs, six included SNPs plus phenotypic factors but not 
age, and 14 a combination of SNPs, phenotypic factors and age. The number of SNPs 
included in the models ranged from 3 to 95.   
 
Development of the risk models and risk of bias 
Details of the methods used to select the predictors and develop each of the risk models  are 
given in Table 1, with additional details of the setting, design, participants, outcome and 
sample size for each study in Supplementary Table S1. The majority of the risk models (n = 
18) were developed or validated in white or European individuals. The others were developed 
or validated in Japanese (n = 4), Korean (n = 3), Chinese (n = 3) and Taiwanese (n = 1) 
populations.  
 
A summary of the assessment of the risk of bias based on the four domains from the 
CHARMS checklist (study population, predictors, outcome and sample size and missing 
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data) is shown in Table 2. Overall we found 12 risk models to be at low risk of bias, 10 at 
unclear risk and five at high risk.  
 
Risk of bias within the study participant domain was variable between studies. Those judged 
to be at unclear or high risk of bias reflected limited or missing details on the inclusion and 
exclusion criteria used to define study participants and/or use of cases or controls not 
representative of the general population, for example recruiting spouses or individuals 
attending outpatient hospital clinics as controls, or recruiting cases from adjuvant 
chemotherapy clinical trials.  
 
When considering selection of predictors, the majority of the models (n = 18) included SNPs 
identified for inclusion from new or previously published genome-wide association studies 
(GWAS) in European or Asian-ancestry populations. In six, the authors had used GWAS 
studies from European or Asian populations to identify SNPs associated with CRC risk and 
then selected a subset of these SNPs for inclusion in the risk model on the basis of the 
associations with disease risk in an independent Japanese or Taiwanese population. Although 
this method was used to identify SNPs that may be associated with risk in non-European 
populations, given the small sample sizes of many of the studies and low statistical power this 
approach potentially excludes SNPs that are associated with risk in these populations. Two 
models(17) were developed on the basis of a GWAS study in a Korean population by 
selecting SNPs with evidence of association at the p<10
-6 
significance level (which is less 
conservative than the conventionally accepted genome-wide level of significance, p<5x10
-8
 
level for a GWAS study). A further three studies (18–20) selected SNPs based on plausible 
biological mechanisms leading to CRC and epidemiological studies (folate metabolism, DNA 
repair and breakdown of carcinogenic compounds, insulin-like growth factor and insulin). 
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One of these, the model by Jung et al.,(20) included both SNPs related to insulin metabolism 
and dietary fatty acids, potentially overestimating the risk for individuals with the risk allele.  
 
Of the 20 models which include phenotypic risk factors, with or without age, in addition to 
SNPs, four used regression analyses to select which factors to include(15,18,20,21), one a 
bootstrap forest prediction model(19), and three(22,23) used risk factors identified from 
previous risk models. However, for the majority (n = 12) of models the publications included 
few details about how phenotypic factors were selected, and whether all those that had been 
considered were included in the final model. As a consequence, many do not include 
established risk factors for CRC.  
 
The outcome (CRC) was defined histologically or from cancer registries in all studies, 
reducing the risk of bias due to case misclassification All studies reported numbers of cases 
and controls used in their development and/or validation analyses. Three included fewer than 
150 cases (and hence had low statistical power). Only five studies adequately described how 
they dealt with missing data, so we cannot be certain that this was done appropriately in the 
remaining studies.  
 
Discrimination and calibration of the risk models 
Discrimination, as measured by the AUROC or C-statistic, was reported for 27 of the 29 risk 
models and calibration reported for four. The discrimination values are summarized 
graphically in Figure 1 and given in Supplementary Table S2, in which models are divided 
into those that include SNPs only and those that combine SNPs with phenotypic variables 
with or without age and whether the discrimination was assessed in the development 
population, bootstrap or a random-split sample, or in an external population or non-random 
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split sample. Where multiple AUROCs or C-statistics for the same model were reported for 
more than one method, measurement in the development populations always gave the highest 
discrimination, followed by that in bootstrapping or random split-sample validation studies 
and then in external populations. Where model performance was included for both men and 
women, discrimination was higher in men (0.59 in men compared with 0.56 in women(24), 
0.63 in men compared with 0.62 in women(25), and 0.70 in men compared with 0.60 in 
women(17)). 
 
Among the eight models that include only SNPs, the discrimination of seven was reported in 
external populations. This ranged between 0.56 and 0.60 in real-life populations and 0.63 in 
simulated populations. Of those assessed in real-life populations, the three considered at low 
risk of bias (Dunlop et al.,(26) Ibanez-Sanz et al.(21), and Smith et al.(23)) all have reported 
AUROCs of 0.56-0.57.  Of the 19 risk models incorporating both SNPs and phenotypic 
variables, the models created by Procopciuc et al.(18),  Jung et al., (20) and Shiao et al., (19), 
have the highest reported discrimination with AUROCs of 0.90 (95% CI, 0.86 - 0.93) in the 
development population, 0.93 in the development population and 0.85 in cross-validation 
respectively. In all three cases the SNPs were selected on the basis of candidate-gene 
association studies as opposed to GWAS studies. The models by Procopciuc et al. and Shiao 
et al were also developed in a small case-control studies with only 150 and 53 cases and 162 
and 53 controls respectively, thus the resulting models are likely subject to a high degree of 
overfitting.    
 
In the remaining models, in which the SNP selection was based on published GWASs, the 
AUROC in split sample validation or external validation in independent datasets ranged 
between 0.61 to 0.63 in models excluding age and 0.56 to 0.70 in those including age. The 
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best performing model in an independent validation population was the model by Smith et al. 
(23). Calibration was reported for only four of the 29 risk models. In three, the numbers of 
predicted colorectal cancers were in line with the observed numbers with non-significant p 
values of 0.086(18)  and 0.336(27) under a Hosmer–Lemeshow statistic and 0.09  under a 
Grønnesby and Borgan test(22) respectively. Smith et al.,(23) assessed calibration 
graphically and found that the genetic risk score alone (Smith 2018a) was poorly calibrated, 
with over-estimation of risk for those in the top decile of risk. After re-calibration, however, 
both the genetic risk score alone and the genetic plus phenotypic models were well calibrated. 
 
Incremental improvement of genetic over family history and/or phenotypic risk factors  
Of the models that combined SNPs with family history and/or phenotypic risk factors, 15 
compared the discrimination of models including SNPs, family history and phenotypic risk 
factors either alone or in combination(Table 3). Together these showed that adding SNPs to 
family history and/or phenotypic variables, and vice versa, leads to an increase in the 
AUROC of between 0.01 to 0.06. For example, in a cross-validation sample of a Spanish 
population, Ibanez-Sanz et al., report an AUROC of 0.61 (95% CI, 0.59-0.64) for their 
environmental risk score comprising alcohol use, family history of CRC, BMI, physical 
exercise, red meat and vegetable intake, and NSAIDs/aspirin use and an AUROC of 0.56 
(95% CI, 0.54-0.58) for their genetic risk score comprising 21 SNPs. For the combined risk 
score, they report an AUROC of 0.63 (95% CI, 0.60-0.66)(21). Iwasaki et al., (22), Xin et al., 
(27) and Weigl et al.,(15) additionally reported that adding genetic risk factors to a model 
including phenotypic risk factors increased the mean integrated discrimination improvement 
(IDI) by 0.015 (95% CI 0.0044 to 0.027), 0.031 (95% CI 0.023 to 0.039) and 0.04 (95% CI 
0.03-0.05) respectively and the mean continuous net reclassification index (NRI) by 0.39 
(95% CI 0.17 to 0.58), 0.317 (95% CI 0.225 to 0.408) and 0.29 (95% CI 0.14 to 0.43) 
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respectively. The study by Smith et al., in which a genetic risk score incorporating 41 SNPs 
identified from previous GWAS studies was added to two previously published phenotypic 
risk scores including age and family history of CRC (28,29) found that the genetic risk score 
did not meaningfully improve model discrimination. They did not report the IDI or NRI but 
overall the addition of genetic information resulted in 4-5% of individuals having a change in 
absolute risk of ≥ 0.3%. For those with an initial estimated absolute risk of <1%, this 
percentage was 3% and for those with an estimated absolute risk ≥1% 25-33% had a change 
in absolute risk of ≥ 0.3%. 
 
Impact of stratifying populations for screening based on genetic risk 
Eight studies assessed the potential impact of using the risk models to determine the starting 
age for screening. Seven of these calculated either the difference in recommended starting 
age for those at low or high risk or the years earlier those at high risk would be invited. These 
are summarised in Table 4.  Considering SNPs alongside family history would result in 
individuals in the highest quintile of risk, for example, being invited between 13 and 21 years 
earlier, with the difference between the invitation ages of the highest quintile being and 
lowest quintile between 13 and 27 years. In all cases where estimates were provided for SNPs 
alone, family history alone, or SNPs and family history combined, the range was greater for 
SNPs than family history and greater for both combined than for either individually. Jenkins 
et al., (30) additionally estimated that if those in the highest quintile of risk were invited for 
screening at age 46 and those in the lowest quintile at age 59, 3.32 million people would be 
screened earlier, of which 8000 of those would be diagnosed with CRC, and 8.76 million 




The eighth study compared the size of the English population eligible for screening and the 
number of CRC cases potentially detectable using age-based screening and personalised 
screening in which eligibility is determined by absolute risk calculated using age and the 
Frampton et al. risk score(12). In a simulated population aged 55-69, 61% of men and 62% of 
women would be eligible for age-based screening (≥ 60 years) and 79% and 77% respectively 
of CRC cases would be diagnosed in this subset. With screening based on the genetic risk 
score (≥ average risk for an individual aged 60 (men 1.96%, women 1.19%)), 45% of men 
and 45% of women would be eligible for screening with 69% and 69% of CRC cases being 
identified. This translates into 16% fewer men and 17% fewer women being eligible for 




We  have identified 29 risk models that incorporate common genetic variants to estimate 
future incidence of CRC in average-risk populations and that have either published measures 
of performance or estimates of the implications of using them for stratified screening. In 
external independent validation datasets, the three models considered at low risk of bias that 
include SNPs identified from GWAS studies all had similar discrimination (AUROC 0.56-
0.57) (Dunlop et al.,(26) Ibanez-Sanz et al.(21), and Smith et al.(23)). Among the models that 
included SNPs in combination with other risk factors, the AUROC in split sample or external 
validation ranged between 0.61 to 0.63 in models excluding age and 0.56 to 0.70 in those 
including age. The model with the highest reported discrimination in an independent 
validation population was the model by Smith et al. that included 41 SNPs alongside age, 
diabetes, multi-vitamin usage, family history, years of education, BMI, alcohol intake, 
physical activity, NSAID usage, red meat intake, smoking and oestrogen use in women(23).  
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Only four reported data on model calibration. The addition of SNPs to risk scores already 
including family history and/or phenotypic variables increased discrimination by 0.01 to 0.06. 
Although this represents a modest increase in discrimination measured in terms of the 
AUROC, such differences can lead to substantial changes in risk stratification in the 
population, as illustrated by continuous NRI values of 0.3 to 0.4 seen in this review and 
demonstrated in the context of other diseases(31). Public health modelling within the studies 
suggest that if the models were used to determine the starting age for screening, this would 
result in individuals in the top 20% for risk being invited up to 23 years earlier than if 
determined by age-based criteria only, with the difference in age at invitation between the 
highest and lowest risk quintiles being several years greater for models including SNPs alone 
than for models including family history alone, and the difference for models including both 
SNPs and family history greater than that for models including either SNP or family history. 
 
Strengths and Limitations 
The main strengths of this review are the comprehensive literature search that included both 
subject headings and free text, and the systematic approach we used to screen papers for 
inclusion. The inclusion of more than one risk model from many of the published papers also 
enabled us to make comparisons between models that included different groups of risk 
factors or had been developed using different statistical methods. Although this approach 
enabled us to identify 23 risk models that have been published since our earlier review, we 
cannot exclude the possibility that there are others that we did not identify. Genetic research 
is also a rapidly advancing field with new papers reporting new genetic variants that could be 




Other limitations of this review relate to the studies themselves. Most of the risk models were 
developed and/or tested in case-control studies. Estimates of absolute risk of developing CRC 
are therefore not possible and the collection of phenotypic risk factors will be subject to both 
recall and responder bias, potentially increasing the apparent discrimination. Conversely, in 
many, the matching variables were not included as covariates within the risk models and this 
may have resulted in underestimation of discrimination(32). The risk models also varied 
substantially in relation to size, selection of cases and controls and variables considered for 
inclusion. This heterogeneity meant it was not possible to assess whether, for example, the 
number of SNPs affected the performance of the models. Furthermore, most risk models were 
developed and/or tested in either European, Chinese or Japanese populations. The risk models 
in this review may therefore not be applicable to other population groups.  
 
There was also heterogeneity in how the SNPs and phenotypic factors were selected and 
combined into risk scores, which ultimately impacts their performance in independent 
samples. For several models SNP selection was based on small sizes and/or there was limited 
detail on how lifestyle/hormonal risk factors were selected. Similarly, several models did not 
include well-established risk factors for CRC. Almost all, however, assumed that the 
associations of the SNPs are independent from each other and that risk follows an additive 
model on the log-Risk scale. These assumptions are generally considered to be robust(33) and 
many of the authors describe how they had sought to remove SNPs in linkage disequilibrium 
or associated with factors on the genetic pathway. In the absence of evidence of interactions, 
the models also assume that the strengths of associations for each SNP with CRC are constant 





Finally, in relation to the performance measures for the models, discrimination for many had 
only been assessed in the development population, no data on discrimination has been 
published for the genetic model with the largest number of SNPs(34), only four models 
reported data on calibration, and only two included estimates of net reclassification. As 
illustrated by the lower AUROCs seen in development populations when compared with the 
performance of the same models from bootstrapping or cross-validation, the performance of 
all prediction models is overestimated due to overfitting when both model development and 
performance assessment use the same data set, particularly in studies with small sample 
sizes(35). Additionally, while the AUROC or other measures of discrimination are important 
when considering how well individuals can be ranked in terms of predicted risk, without 
measures of calibration or reclassification it is not possible to assess how closely the 
estimated risks match the observed risks, how much including different factors in the risk 
scores influences the classification of individuals or whether the models stratify correctly into 
high/low categories of absolute risk that are of clinical importance.  
 
Implications for future research 
This review shows that a large number of risk scores incorporating common genetic markers 
have been developed to estimate future risk of CRC and suggests that many of these are 
better at discriminating between those at higher and lower risk of CRC than age alone, family 
history alone, or risk scores incorporating only phenotypic risk factors. As has been described 
previously(9,36), risk models such as these could be used to stratify the general population 
into risk categories, based either on estimates of absolute risk for those models including age 
or relative risk for those excluding age, to allow screening and preventive strategies to be 
targeted at those most likely to benefit. While the findings of this review therefore suggest 
that future risk prediction in colorectal cancer will improve with the inclusion of polygenic 
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risk factors, it remains uncertain how these models would perform in real-life settings and 
whether the increase in discriminatory performance and wider range of ages at which 
individuals would become eligible for screening that could be achieved through the inclusion 
of genetic variables translates into improved health of the population or the cost effectiveness 
of a screening programme. 
 
Firstly, many of these models have not been externally validated and very few have had 
calibration assessed.  As described above, these steps are essential before risk models can be 
incorporated into practice. To enable direct comparisons between the models, ideally the 
models identified in this review with the greatest number of SNPs and those with the highest 
reported discrimination would be assessed in a single independent cohort. However, the 
predictive ability of risk models is known to vary between populations and the risk of 
developing CRC varies substantially worldwide(37). The choice of models for independent 
validation will therefore depend on the population of interest and these analyses should be 
performed in populations similar to those in which use of the model is being considered. This 
is particularly important in the context of genetic risk models.   Comparisons between the 
population genetics of different ethnic groups have shown that the estimated associated risks 
and population frequencies of SNPs can vary substantially with ethnicity(38,39) and the 
overall magnitude of association of polygenic risk scores derived from GWAS in European-
ancestry populations, as is the case for most models for CRC, may differ when applied to 
other populations(40). As highlighted by De La Vega and Bustamante, to avoid further 
inequities in health outcomes, the inclusion of diverse populations in CRC research, unbiased 




Secondly, further methodological studies are required to improve genome-wide risk 
prediction in order to understand the potential benefits of including increasing numbers of 
SNPs, together with other rare moderate/high risk genetic variants and established or new 
lifestyle/environmental risk factors, as has been done for other cancers(42). These also 
include exploring more sophisticated statistical methods for developing polygenic risk 
scores(43), and novel methods such as machine learning approaches for combining the 
effects of diverse risk factors(40). Thirdly, there was substantial variation in the reporting of 
the studies in this review. Encouraging the use of reporting guidelines, such as the Genetic 
Risk Prediction Studies (GRIPS) statement(44,45) that includes a checklist of 25 items, 
would improve the transparency, quality, and completeness of the reporting of new models 
and facilitate future syntheses in this field.  
 
Finally, the assessment of model performance is only one component when considering 
whether risk models are ready for clinical use; the context in which the model will be used, 
including the costs of measuring additional risk factors and the risk-benefit of any 
interventions offered, and the wider ethical, legal and social issues around implementation 
must also be considered. To our knowledge, only one study has modelled the potential impact 
of CRC screening based on age and SNPs on preventing deaths from CRC (11). Using age-
specific crude rate of deaths due to CRC in a hypothetical population based on the Australian 
population in 2011 and assuming a 100% attendance rate at screening, that study showed that 
the net effect of inviting individuals for biennial FOBT based on their genetic risk would be 
0.4% more colorectal cancer deaths and 0.2% more years of life lost per person invited to 
screen than inviting those aged between 50 and 74, against a background of 4.9% fewer 
screens, resulting in a 3.1% overall improved efficiency. The risk model used in that study 
was the model by Jenkins et al., 2006 that includes 45 SNPs and had an AUROC of 0.63 in a 
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simulated population. It is likely, therefore, that similar improvements in efficiency would be 
seen with other models, many of which have reported AUROCs of greater than 0.63. 
However, that study did not consider the costs of implementing stratified screening, 
competing risks of death or the psychological harms associated with screening, uniform 
attendance across risk groups was assumed, and no data was included on the calibration of 
the model. Further modelling studies are therefore needed to assess the cost-effectiveness and 
differences in quality adjusted life years (QALYs) and implementation studies to asses risk-
appropriate screening participation and the psychosocial consequences of this approach.  
 
By identifying the published risk models for CRC that include common genetic variants and 
demonstrating the potential public health benefits of using such models to determine the 
starting age for screening, this study provides valuable evidence to support investment in this 
further research.   
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Table 1. Summary of risk models 
Author, 
year 
Country Outcome Factors included in score 

























--- --- 3 
Frampton 
2016 
UK (v) CRC 37 SNPs Published GWAS studies from 
European populations 
Weighted allele model 
weighted by published 
log odds 





CRC 6 SNPs Published GWAS studies from 
European populations followed 
by logistic regression 
Unweighted allele 
counting model 







CRC 95 SNPs GWAS study  Weighted allele model 
weighted by study 
derived weights 





CRC 21 SNPs Published GWAS studies 




(weighted allele models 
weighted by published 
log-odds and study 
derived log-odds similar 
so not reported)  






CRC 45 SNPs Published GWAS studies from 
European populations 
Weighted allele model 
weighted by published 
log odds 





CRC 41 SNPs Published GWAS studies from 
predominantly European and 
white populations 
Weighted allele model 
weighted by published 
log odds 
--- --- 3 
Wang 2013  Taiwan 
(d, v) 
CRC 16 SNPs Published GWAS studies from 
Asian populations followed by 
replication analysis and jack-
knife selection 
Logistic regression --- --- 1b 
Xin 2018a China 
(d, v) 
CRC 14 SNPs Published GWAS studies from 
European or Asian populations 
Unweighted allele 
counting model;  
--- --- 3 
26 
 
Weighted allele model 
weighted by published 
log odds; Weighted allele 
model weighted by study 
derived weights 





CRC 21 SNPs, family history of CRC, alcohol 
use, BMI, physical exercise, red meat and 
vegetable intake, NSAIDs/aspirin use 
Published GWAS studies 




(weighted allele models 
weighted by published 
log-odds and study 
derived log-odds similar 
















63 SNPs, height, BMI, education, history 
of type 2 diabetes mellitus, smoking status, 
alcohol consumption, regular aspirin use, 
regular NSAID use, regular use of 
postmenopausal hormones, smoking, 
intake of fibre, calcium, folate, processed 
meat, red meat, fruit, vegetables, total-
energy, physical activity 
Published GWAS studies from 
predominantly European and 
Asian populations 
Weighted allele model 
weighted by study 
derived estimated 
regression coefficients  
No details given 











CRC (male) 63 SNPs, height, BMI, education, history 
of type 2 diabetes mellitus, smoking status, 
alcohol consumption, regular aspirin use, 
regular NSAID use, smoking, intake of 
fibre, calcium, folate, processed meat, red 
meat, fruit, vegetables, total-energy, 
physical activity 
Published GWAS studies  from 
predominantly European and 
Asian populations 
Weighted allele model 
weighted by study 
derived estimated 
regression coefficients  
No details given 









CRC 7 SNPs, gender, alcohol, fried red meat Candidate genes on metabolic 
pathway 





Xin 2018b China 
(d, v) 
CRC 14 SNPs, smoking status Published GWAS studies from 
European or Asian populations 
Unweighted allele 
counting model 
No details given 







UK (v) CRC 14 SNPs, BMI, smoking, alcohol, fibre 
intake, red meat intake, physical activity 














Genetic plus phenotypic risk factors including age 
Abe 2017 Japan 
(d, v) 
CRC 11 SNPs, age, sex, referral pattern, current 
BMI, smoking, alcohol consumption, 
regular exercise, family history of 
colorectal cancer in a first degree relative, 
and dietary folate intake 
Published GWAS studies from 
European and East Asian 




No details given 









CRC 10 SNPs, age, gender, first degree relative 
with CRC 




No details given 

















CRC 6 SNPs, age, referral pattern, current BMI, 
smoking, alcohol consumption, regular 
exercise, family history of CRC, dietary 
folate intake  
Published GWAS studies from 
European populations followed 
by logistic regression 
Unweighted allele 
counting model 
No details given 





Hsu 2015 USA and 
Germany 
(d, v) 
CRC 27 SNPs, age, sex, family history of CRC, 
history of endoscopic examinations 
Previous GWAS studies from 





weighted by published 
log-odds similar so not 
reported) 
No details given 









CRC (male) 6 SNPs, age, BMI, alcohol, smoking status Previous published model and 
GWAS from European and East 
Asian populations followed by 
cox proportional hazards 
modelling 
Weighted allele model 
weighted by study 
derived log-transformed 














5 SNPs, age, family history of CRC GWAS study in Korean 
population with significance 
level of p<10-6 
Unweighted allele 
counting model; 
weighted allele model 
weighted by study 
derived beta-coefficients 
No details given 






Jo 2012b  Korea 
(d, v) 
CRC (male) 3 SNPs, age, family history of CRC GWAS study in Korean 
population with significance 
level of p<10-6 
Unweighted allele 
counting model; 
weighted allele model 
weighted by study 
derived beta-coefficients 
No details given 










7 SNPs, age, sex, smoking status, exercise 
status, fasting serum glucose, family 
history of CRC 
Published GWAS studies from 
predominantly European and 




weighted allele model 
weighted by study 
derived beta-coefficients 
No details given 






Jung 2019 USA 
(d) 
CRC 4 SNPs, age, percentage calories from 
saturated fatty acids 
Candidate genes related to 
insulin-growth like factor and 
insulin 
Weighted allele model 
weighted by predictive 
value assessed via 
minimal depth method 
in nested random 






analyses for final 






Li 2015 China (d) CRC 7 SNPs, age, sex, smoking, drinking NHGRI GWAS database Unweighted allele 
counting model; 
No details given 






*Tripod level - 1a – Development only; 1b – Development and validation using resampling; 2a – Random split-sample development and validation; 2b – Non-random split-sample development and validation; 3 – 
Development and validation using separate data; 4 – external validation. CRC – colorectal cancer, SNP - single-nucleotide polymorphism, BMI – body mass index, NSAID – non-steroidal anti-inflammatory drug, 
wGRS – weighted genetic risk score. d = development; v - validation 
** Simulated population 
 
  
weighted allele model 
weighted by study 
derived beta-coefficients 
included 
Shiao 2018 USA  
(d, v) 
CRC 5 SNPs, age, gender, BMI, thiamine, 
MTHFRR 677 expression level, HEI score 
(calories, total fruit, whole fruit, 
vegetables, dark green, total grains, whole 
grains, dairy, protein, oil and nuts, 
saturated fat, sodium, empty calories) 

















CRC 41 SNPs, age, family history Published GWAS studies from 
predominantly European and 
white populations 
Weighted allele model 
weighted by published 
log odds 
Factors included 













CRC 41 SNPs,  age, diabetes, multi-vitamin 
usage, family history, years of education, 
BMI, alcohol intake, physical activity, 
NSAID usage, red meat intake, smoking, 
oestrogen use (women only) 
Published GWAS studies from 
predominantly European and 
white populations 
Weighted allele model 
weighted by published 
log odds 
Factors included 







original model.  
3 





48 SNPs, age, sex, previous colonoscopy, 
physical activity, BMI 
































 + = low risk; ? = unclear risk; - = high risk 
 
  
Author, year Study 
Participants 
Predictors Outcome Sample size and 
missing data 
Overall 
Genetic risk factors alone 
Dunlop 2013a + + + + + 
Frampton 2016 ? + + ? ? 
Hosono 2016a ? ? + ? ? 
Huyghe 2019 + + + ? + 
Ibanez-Sanz 2017a + + + ? + 
Jenkins 2016, 2019 + + + ? + 
Smith 2018a + + + + + 
Wang 2013 ? - + ? - 
Xin 2018a ? + + ? ? 
Genetic plus phenotypic risk factors excluding age 
Ibanez-Sanz 2017b + + + ? + 
Jeon 2018a and b + + + ? + 
Procopciuc 2017 - ? + - - 
Xin 2018b ? ? + ? ? 
Yarnell 2013 ? + + ? ? 
Genetic plus phenotypic risk factors plus age 
Abe 2017 ? + + ? ? 
Dunlop 2013b + ? + + + 
Hosono 2016b ? ? + ? ? 
Hsu 2015b + ? + ? ? 
Iwasaki 2017b + + + ? + 
Jo 2012 a and b ? - + - - 
Jung 2015 + ? + ? ? 
Jung 2019 + - + ? - 
Li 2015 ? ? + ? ? 
Shiao 2018 - ? + - - 
Smith 2018b + + + + + 
Smith 2018c + + + + + 
Weigl 2018 + + + ? + 
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Table 3. Discriminatory performance of models including genomic risk factors only with those including family history and/or phenotypic risk factors only or 
genetic and family history and/or phenotypic risk factors combined 






























Genetic risk factors, 
family history and 
phenotypic risk factors 
combined  
(AUROC (95% CI)) 
Dunlop 2013 0.57      0.59 













0.56 (0.54-0.58)  0.60 (0.57-0.61) 
 
0.61 (0.59-0.64)  0.63 (0.60-0.66) 
Iwasaki 2017 0.63a  0.60a   0.66a  
Jeon 2018a 
(female) 
 0.54 (0.52-0.55)  0.59 (0.58-0.60) 0.60 (0.59-0.61)  0.62 (0.61-0.63) 
Jeon 2018b 
(male) 
 0.53 (0.52-0.54)  0.59 (0.58-0.60) 0.60 (0.59-0.61)  0.63 (0.62-0.64) 
Jo 2012    






Men: 0.73 (0.68-0.77) 
Jung 2015     0.73 (0.69-0.78)  0.74 (0.70-0.78) 
Smith 2018a 
and b 
0.56 (0.55-0.58)   
 0.67 (0.65-0.68) 
Excluding age: 0.52 
(0.51-0.53) 
 0.68 (0.66-0.69) 
Smith 2018a 
and c 
0.57 (0.55-0.58)   
 0.68 (0.67-0.69) 
Excluding age: 0.58 
(0.57-0.60) 
 0.69 (0.67-0.70) 
Li 2015   0.57 (0.55-0.59)   0.59 (0.57-0.61)  
Weigl 2018   0.62   0.67  
Xin 2018b   0.52 (0.50-0.54)   0.61 (0.58-0.63)  
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Table 4. Results of population modelling studies showing the difference in recommended starting age or estimated number of years earlier that individuals 
would be invited to screening if the age of invitation was determined by a risk threshold based on a genetic or phenotypic model 
Author, 
year 
Model specific risk 
threshold used to 
determine starting 







Difference in years in recommended starting age for screening between those in the highest and lowest 
percentiles of risk 
Papers selecting the top 
and bottom 1% of risk 
for comparison 
Papers selecting the top 
and bottom 10% of risk for 
comparison 
Papers selecting the top 
and bottom 20% of risk 
for comparison 
Papers selecting the 
top and bottom 33% of 
risk for comparison 
Hsu 2015 
Average 10 year risk 
of a 50 year old 
(0.91%) 
FH --- 
Men: 5 (44 to 49)* 






Men: 10 (42 to 52) 





0.3% 5 year estimated 
risk 
SNPs --- --- 
Men: 10 (45-55) 





Men: 22 (35 to 57) 










Men: 27 (46 to 73) 
Women: 32 (48 to 80) 
Men: 18 (48 to 66) 










Men: 17 (46 to 63) 
Women: 23 (53 to 76) 
Men: 13 (48 to 61) 
Women: 17 (55 to 72) 
--- 
Jeon 2018 
Average 10 year risk 





Men:17 (38 to 55) 
Women:21 (43 to 64) 
Men: 11 (40 to 51) 





Average 10 year risk 
of a 50 year old 
(1.13% for men and 
0.68% for women) 
SNPs 
Men: 18 (41 to 59) 
Women: 24 (45 to 69) 
Men: 10 (range 44 to 54) 





Average relative risk 
for a 60 year old with 
medium genetic risk 






Years earlier for recommended starting age for those in the highest percentiles 
1% 10% 20% 33% 
Dunlop 
2013 
5% 10 year estimated 
risk 
FH 
Men: >15 (from >75) 
Women: > 12 (from >80) 




























Men: > 23 (from >75) 
Women: >22 (from >80) 




1% 5 year estimated 
risk 
FH --- 
Men: 12 (from 67)* 
Women: 12 (from 73)* 
--- --- 
SNPs --- 
Men: 14 (from 67) 
Women: 14 (from 73) 
Men: 10 (from 67) 





Men: 21 (from 67) 
Women: 25 (from 73) 
Men: 19 (from 67) 





1% 5 year estimated 
risk 
FH --- 
Men: 9 (from 61)* 
Women: 12 (from 71)* 
--- --- 
SNPs --- 
Men: 9 (from 61) 
Women: 12 (from 71) 
Men: 6 (from 61) 





Men: 15 (from 61) 
Women: 18 (from 71) 
Men: 13 (from 61) 





Figure 1. Relative discriminative performance of the risk scores grouped by those including 
only SNPs, those including SNPs plus family history and/or phenotypic risk factors without 
age and those including SNPs plus family history and/or phenotypic risk factors and age. 
Within each of these groups, the models are ordered according to sample size, with larger 
studies being those towards the bottom of each risk model category.  
 

